Zacks Investment Research on MSN16h
GILD Stock Down on Report of Cut in HIV Prevention SpendingShares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Stocktwits on MSN1d
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay UnfazedShares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.
The Health and Human Services Department is weighing plans to drastically cut funding for domestic HIV prevention, The Wall Street Journal reported. + The cuts could af ...
Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...
Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback